Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis

Hyperkalemia often occurs among heart failure (HF) patients, particularly when treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Even modest potassium levels variations raise the risk of mortality and prompt patients to discontinue disease-modifying treatment, as RAASi. Novel pot...

Full description

Saved in:
Bibliographic Details
Published in:European journal of internal medicine 2024-01, Vol.119, p.109-117
Main Authors: Paolillo, Stefania, Basile, Christian, Dell'Aversana, Simona, Esposito, Immacolata, Chirico, Alfonsina, Colella, Angela, Esposito, Gennaro, Santo, Mariafrancesca Di, Fierro, Maria Francesca, Carbone, Francesca, Marzano, Federica, Amato, Chiara, Gargiulo, Paola, Perrone Filardi, Pasquale
Format: Article
Language:English
Subjects:
Heart Failure - complications
Heart Failure - drug therapy
Humans
Hyperkalemia - complications
Hyperkalemia - drug therapy
Potassium - blood
Renal Insufficiency, Chronic - complications
Renin-Angiotensin System - drug effects
Silicates - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperkalemia often occurs among heart failure (HF) patients, particularly when treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Even modest potassium levels variations raise the risk of mortality and prompt patients to discontinue disease-modifying treatment, as RAASi. Novel potassium binders (NPB), patiromer and sodium zirconium cyclosilicate, are effective in reducing potassium levels and are approved for the treatment of hyperkalemia in HF, but whether their use results in a real optimization of HF treatment remains to be seen. The aim of the present meta-analysis was to assess the efficacy of NPB on the optimization of RAASi therapy in HF patients. PubMed, Web of Science and Clinicaltrial.gov were searched without restrictions from inception to 06 August 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. The prespecified primary outcome was the optimization of RAASi therapy in HF patients, defined as the proportion of patients on RAASi at the end of follow-up. Secondary outcomes were hyperkalemia events, reduction in potassium levels, and adverse drugs reactions. Six studies with a total of 1390 patients were included. NPB improved RAASi therapy optimization in HF by 14% (95% CI: 4-26%), decreased hyperkalemia events by 29% (95% CI: 55-92%), and reduced potassium levels by 0.31 mEq/L (95% CI: 0.18-0.44) compared to placebo, maintaining a good safety profile. NPB are effective in allowing RAASi therapy optimization in patients affected by HF, in reducing hyperkalemia events and potassium levels. CRD42022351811 URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=351811.
ISSN:0953-6205
1879-0828
DOI:10.1016/j.ejim.2023.08.022